A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Study sponsor: Satellos Bioscience, Inc. · MSLE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12-30Estimated
Enrollment · participants51Estimated
Source updated2026-10-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.